Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 20;11(4):87-91.
doi: 10.1002/cld.709. eCollection 2018 Apr.

Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis

Kara Wegermann  1 , Anna Mae Diehl  1 , Cynthia A Moylan  1   2
Affiliations
Review

Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis

Kara Wegermann et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current and emerging therapies for NASH. Multiple molecular pathways are involved in NASH pathogenesis Anti‐NASH strategies are shown according to their mechanism of action. Green color indicates agonist; red color indicates antagonist. Abbreviations: CTGF, connective tissue growth factor; FGF19, fibrosis growth factor 19; IBAT, ileal bile acid transporter; LPS, lipopolysaccharide; PDE, phosphodiesterase.
See this image and copyright information in PMC

References

    1. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology 2015;61:1547‐1554. - PubMed
    1. Angulo P, Kleiner DE, Dam‐Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389‐397.e10. - PMC - PubMed
    1. Berk PD, Verna EC. Nonalcoholic fatty liver disease: lipids and insulin resistance. Clin Liver Dis 2016;20:245‐262. - PMC - PubMed
    1. Marra F, Svegliati‐Baroni G. Lipotoxicity and the gut‐liver axis in NASH pathogenesis. J Hepatol 2018;68:280‐295. - PubMed
    1. Safadi R, Konikoff FM, Mahamid M, Zelber‐Sagi S, Halpern M, Gilat T, et al. The fatty acid‐bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2085‐2091.e1. - PubMed